AccuStem Sciences appoints Sean McDonald as independent director; board now five members

Accustem Sciences Inc.

Sean McDonald appointed to AccuStem board effective Nov. 14, 2022; board expanded from four to five members.
McDonald currently CEO of Ocugenix, a therapeutics company focusing on ocular diseases.
He previously scaled Automated Healthcare (acquired by McKesson) and served as CEO of Precision Therapeutics.
McDonald was a director at Respironics before its $5.1B acquisition by Philips.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sean McDonald

independent director

ACUT · Accustem Sciences Inc.

Effective: 2022-11-14
Filed: November 16, 2022, 6:59 PM ET

On November 14, 2022, the Board of Directors (the “Board”) of AccuStem Sciences, Inc. (the “Company”) increased the size of the Board to five members and elected Sean McDonald as an independent director, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sean McDonald was elected as independent director at Accustem Sciences Inc..

Action: elected
Role: independent director

Exact text from the filing

On November 14, 2022, the Board of Directors (the “Board”) of AccuStem Sciences, Inc. (the “Company”) increased the size of the Board to five members and elected Sean McDonald as an independent director, for a term continuing to the Company’s next annual meeting of shareholders, when all directors will be subject to election by shareholders.

View on SEC.gov

Accustem Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.